Caricamento...
Does Denosumab Change the Giant Cell Tumor Treatment Strategy? Lessons Learned From Early Experience
BACKGROUND: Although giant cell tumors (GCTs) are benign, their aggressiveness and tendency to recur locally challenge the orthopaedic surgeon’s ability to perform joint-preserving intralesional surgery with an acceptably low risk of local recurrence. Denosumab has emerged as a possible medical trea...
Salvato in:
| Pubblicato in: | Clin Orthop Relat Res |
|---|---|
| Autori principali: | , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Wolters Kluwer
2018
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6259809/ https://ncbi.nlm.nih.gov/pubmed/30794215 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11999.0000000000000243 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|